LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme

Stock News05-08

LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total of 44.3916 million unlisted shares held by these shareholders into H shares. On May 7, 2026, the company received a "Filing Notice for the 'Full Circulation' of Unlisted Shares of Nanjing Leads Biolabs Biotechnology Co., Ltd." issued by the CSRC, dated April 27, 2026. According to the filing notice, if the company does not complete the conversion and listing within 12 months from the date of the notice's issuance and intends to proceed further, it must update its filing materials. On May 8, 2026, the company further submitted filing materials to the CSRC regarding the conversion of 1.2215 million unlisted shares held by one shareholder into H shares. The company will apply to The Stock Exchange of Hong Kong for the conversion and listing, which will be completed only after fulfilling the relevant procedures required by the Exchange and other pertinent regulatory bodies. In accordance with the company's articles of association, no separate general meeting is required to approve the conversion and listing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127882981?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127882981","market":"nz","top_or_hot":-1,"title":"LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total of 44.3916 million unlisted shares held by these shareholders into H shares. On May 7, 2026, the company received a \"Filing Notice for the 'Full Circulation' of Unlisted Shares of Nanjing Leads Biolabs Biotechnology Co., Ltd.\" issued by the CSRC, dated April 27, 2026. According to the filing notice, if the company does not complete the conversion and listing within 12 months from the date of the notice's issuance and intends to proceed further, it must update its filing materials. On May 8, 2026, the company further submitted filing materials to the CSRC regarding the conversion of 1.2215 million unlisted shares held by one shareholder into H shares. The company will apply to The Stock Exchange of Hong Kong for the conversion and listing, which will be completed only after fulfilling the relevant procedures required by the Exchange and other pertinent regulatory bodies. In accordance with the company's articles of association, no separate general meeting is required to approve the conversion and listing.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-08 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total of 44.3916 million unlisted shares held by these shareholders into H shares. On May 7, 2026, the company received a \"Filing Notice for the 'Full Circulation' of Unlisted Shares of Nanjing Leads Biolabs Biotechnology Co., Ltd.\" issued by the CSRC, dated April 27, 2026. According to the filing notice, if the company does not complete the conversion and listing within 12 months from the date of the notice's issuance and intends to proceed further, it must update its filing materials. On May 8, 2026, the company further submitted filing materials to the CSRC regarding the conversion of 1.2215 million unlisted shares held by one shareholder into H shares. The company will apply to The Stock Exchange of Hong Kong for the conversion and listing, which will be completed only after fulfilling the relevant procedures required by the Exchange and other pertinent regulatory bodies. In accordance with the company's articles of association, no separate general meeting is required to approve the conversion and listing.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09887","symbol_name":"维立志博-B","start_time":0,"source_url":"","article_id":"1127882981","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127882981","pubTimestamp":1778243428,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09887":"维立志博-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK1161":"生物科技","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元"},"translate_title":"LEADS BIOLABS-B收到证监会H股全流通备案通知书并计划实施该计划","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total of 44.3916 million unlisted shares held by these shareholders into H shares. On May 7, 2026, the company received a \"Filing Notice for the 'Full Circulation' of Unlisted Shares of Nanjing Leads Biolabs Biotechnology Co., Ltd.\" issued by the CSRC, dated April 27, 2026. According to the filing notice, if the company does not complete the conversion and listing within 12 months from the date of the notice's issuance and intends to proceed further, it must update its filing materials. On May 8, 2026, the company further submitted filing materials to the CSRC regarding the conversion of 1.2215 million unlisted shares held by one shareholder into H shares. The company will apply to The Stock Exchange of Hong Kong for the conversion and listing, which will be completed only after fulfilling the relevant procedures required by the Exchange and other pertinent regulatory bodies. In accordance with the company's articles of association, no separate general meeting is required to approve the conversion and listing.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127882981","isCrawlerRequest":true}